S
Salvatore Siena
Researcher at University of Milan
Publications - 572
Citations - 62791
Salvatore Siena is an academic researcher from University of Milan. The author has contributed to research in topics: Colorectal cancer & Panitumumab. The author has an hindex of 91, co-authored 524 publications receiving 53868 citations. Previous affiliations of Salvatore Siena include Novartis & Indiana University.
Papers
More filters
Journal ArticleDOI
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
Giulia Siravegna,Andrea Sartore-Bianchi,Benedetta Mussolin,Andrea Cassingena,Alessio Amatu,Luca Novara,Michela Buscarino,Giorgio Corti,Giovanni Crisafulli,Alice Bartolini,Federica Tosi,Mark G. Erlander,F. Di Nicolantonio,Salvatore Siena,Alberto Bardelli +14 more
TL;DR: Urine-based genetic testing allows tracing of tumor-specific oncogenic rearrangements and could be effectively applied to non-invasively monitor tumor evolution during therapy to monitor minimal residual disease after surgery with curative intent in patients whose tumors carry gene fusions.
Journal ArticleDOI
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Andrea Sartore-Bianchi,Katia Bencardino,Andrea Cassingena,Filippo Venturini,C. Funaioli,Tiziana Cipani,Alessio Amatu,Lisa Pietrogiovanna,Roberta Schiavo,F. Di Nicolantonio,Salvatore Artale,Alberto Bardelli,Salvatore Siena +12 more
TL;DR: This review will focus on current knowledge regarding the molecular landscape of mCRC including and beyond KRAS, and will summarize novel rationally-developed combinatorial regimens that are being evaluated in early clinical trials.
Journal ArticleDOI
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients
Andrea Sartore-Bianchi,Filippo Pietrantonio,Alessio Amatu,Massimo Milione,Andrea Cassingena,Silvia Ghezzi,Marta Caporale,Rosa Berenato,Chiara Falcomatà,Alessio Pellegrinelli,Alberto Bardelli,Michele Nichelatti,Federica Tosi,Filippo de Braud,Federica Di Nicolantonio,Ludovic Barault,Salvatore Siena +16 more
TL;DR: In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents and their combination could enhance patient selection in this setting.
Journal ArticleDOI
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).
Riccardo Ricotta,Antonella Verrioli,Silvia Ghezzi,Luca Porcu,Axel Grothey,Alfredo Falcone,Eric Van Cutsem,Guillem Argiles,Antoine Adenis,Marc Ychou,Carlo Barone,Olivier Bouché,Marc Peeters,Yves Humblet,Laurent Mineur,Alberto Sobrero,Joleen M. Hubbard,Chiara Cremolini,Hans Prenen,Josep Tabernero,Hajer Jarraya,Thibault Mazard,Sophie Deguelte-Lardiere,Konstantinos Papadimitriou,Marc Van den Eynde,Alessandro Pastorino,Daniela Redaelli,Katia Bencardino,C. Funaioli,Alessio Amatu,Giulia Carlo-Stella,Valter Torri,Andrea Sartore-Bianchi,Angelo Vanzulli,Salvatore Siena +34 more
TL;DR: Lung metastases cavitation represents a novel radiological marker of favourable outcome that deserves consideration and is found to predict favourable outcome to regorafenib in exploratory multivariable models.
Journal Article
Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system.
M. Di Nicola,Salvatore Siena,Paolo Corradini,M. Bregni,Marco Milanesi,Michele Magni,P. A. Ruffini,Fernando Ravagnani,Corrado Tarella,A. M. Gianni +9 more
TL;DR: These results, attained with the newly available Super MACS system, compare favorable with previous techniques because they show the feasibility of eliminating F-NHL cells from blood cell transplants without relevant nonspecific loss of hematopoietic progenitors.